CELSENTRI 150MG TABLETS
MARAVIROC
What it does
Maraviroc is a medication used to help manage HIV infection by blocking the virus from entering healthy cells.
Commonly used for: HIV infection (human immunodeficiency virus)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:10:02 · updated 2026-08-03 04:10:20
Drug Interactions
14Severe (2)
Fosamprenavir And Fosamprenavir Potentially Decreases The Exposure To Maraviroc - decreases exposure
Maraviroc potentially decreases the exposure to fosamprenavir and fosamprenavir potentially decreases the exposure to maraviroc. Avoid.
Maraviroc - decreases exposure
StJohn’swortispredictedtodecreasetheexposureto maraviroc.Avoid.rTheoretical
Moderate (6)
Maraviroc - decreases exposure
Belzutifan is predicted to decrease the exposure to maraviroc. Avoid or adjust dose.
Maraviroc - decreases exposure
Cenobamateispredictedtodecreasetheexposureto maraviroc.Adjustdose.oTheoretical
Maraviroc - increases exposure
Idelalisibmarkedlyincreasestheexposuretomaraviroc. Adjustdose.rTheoretical
Maraviroc - decreases exposure
Mitotane is predicted to decrease the exposure to maraviroc. Adjust dose.
Maraviroc - increases exposure
Vemurafenib is predicted to increase the exposure to maraviroc. Use with caution or avoid. Theoretical Measles, mumps and rubella vaccine, live → see live vaccines Mebendazole
Maraviroc - decreases exposure
Rifampicin is predicted to decrease the exposure to maraviroc. Adjust dose.
Unknown (6)
Maraviroc - increases exposure
Cobicistat markedly increases the exposure to maraviroc. Refer to specialist literature.
Maraviroc - decreases exposure
Bosentanispredictedtodecreasetheexposuretomaraviroc. Avoid.oTheoretical
Maraviroc - increases exposure
Atazanavir moderately to markedly increases the exposure to maraviroc. Refer to specialist literature.
Maraviroc - increases exposure
Ritonavir markedly increases the exposure to maraviroc. Refer to specialist literature.
Maraviroc - decreases exposure
Efavirenzdecreasestheexposuretomaraviroc.Referto specialistliterature.rTheoretical
Maraviroc - decreases exposure
Etravirine slightly decreases the exposure to maraviroc. Refer to specialist literature.
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About this medicine
Maraviroc is a medication used to help manage HIV infection by blocking the virus from entering healthy cells.
What it treats
- HIV infection (human immunodeficiency virus)
How it works
It works by blocking certain receptors on the surface of cells that HIV uses to enter and infect them.
Who it's for
This medication is for adults and children who are infected with HIV and need treatment.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Maraviroc
BNF-referencedMaraviroc is a CCR5 antagonist used primarily in the treatment of HIV infection. It works by blocking the CCR5 co-receptor on the surface of T-cells, preventing HIV from entering and infecting these cells. This medication is particularly indicated for patients with CCR5-tropic HIV-1 strains who have experienced treatment failure with other antiretroviral therapies.
Indications
- HIV infection resistant to other protease inhibitors
- Combination therapy with other antiretroviral drugs in treatment-experienced patients with detectable CCR5-tropic HIV-1
Dosage
Children: Refer to the BNF for Children for appropriate dosing information.
Adults: 500 mg twice daily.
Mechanism of action
Maraviroc selectively binds to the CCR5 co-receptor on CD4+ T lymphocytes, inhibiting the entry of CCR5-tropic HIV-1 into these cells. This blockade prevents the virus from utilizing the CCR5 co-receptor necessary for its fusion and subsequent entry into the host cells, thus halting the infection process.
Pharmacodynamics
The pharmacodynamics of maraviroc involve its ability to selectively inhibit the binding of HIV to the CCR5 receptor, which is crucial for the virus's entry into immune cells. By preventing this interaction, maraviroc reduces the viral load and helps to preserve immune function in patients infected with CCR5-tropic HIV.
Pharmacokinetics
Maraviroc is well-absorbed when taken orally, with peak plasma concentrations occurring approximately 0.5 to 4 hours post-dose. It is extensively metabolized by the liver, primarily through CYP3A4, and has a half-life of about 14 to 18 hours. The drug is primarily excreted through feces, with renal excretion accounting for a small percentage. Liver function should be monitored due to potential hepatotoxic effects.
Adverse effects
- Abdominal pain
- Anaemia
- Appetite decreased
- Asthenia
- Depression
- Diarrhoea
- Flatulence
- Headache
- Insomnia
- Nausea
- Rash
- Hyperamylasaemia
- Influenza-like illness
- Dehydration
- Hyperbilirubinaemia
- Intracranial haemorrhage
- Bleeding tendency
Interactions
- Maraviroc + fosamprenavir: severe (decreases exposure)
- St. John's Wort + maraviroc: severe (decreases exposure)
- Belzutifan + maraviroc: moderate (decreases exposure)
- Cenobamate + maraviroc: moderate (decreases exposure)
- Idelalisib + maraviroc: moderate (increases exposure)
- Mitotane + maraviroc: moderate (decreases exposure)
- Vemurafenib + maraviroc: moderate (increases exposure)
- Rifampicin + maraviroc: moderate (decreases exposure)
- Cobicistat + maraviroc: unknown (increases exposure)
- Bosentan + maraviroc: unknown (decreases exposure)
Precautions
- Caution in patients with abnormal liver function tests or signs of liver injury
- Monitor liver function before treatment, then every 2 weeks for 3 months, then monthly until 48 weeks, then every 8 to 12 weeks thereafter
- Caution in patients with renal impairment (eGFR less than 80 mL/minute/1.73 m2)
- Consider delaying treatment if serum transaminases are greater than 5 times the upper limit of normal
Pregnancy
Manufacturer advises use only if potential benefit outweighs risk due to toxicity in animal studies.
Breast-feeding
Unknown, consult product literature.
Storage
Store in a cool, dry place, protected from light.
Formulations
- Maraviroc 25 mg tablets
- Maraviroc 75 mg tablets
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Maraviroc
PubChem CID 3002977Molecular formula: C29H41F2N5O
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.